A citation-based method for searching scientific literature

Julian P T Higgins, Douglas G Altman, Peter C Gøtzsche, Peter Jüni, David Moher, Andrew D Oxman, Jelena Savovic, Kenneth F Schulz, Laura Weeks, Jonathan A C Sterne. BMJ 2011
Times Cited: 13433







List of co-cited articles
72 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. PLoS Med 2009
21

Bias in meta-analysis detected by a simple, graphical test.
M Egger, G Davey Smith, M Schneider, C Minder. BMJ 1997
14

Measuring inconsistency in meta-analyses.
Julian P T Higgins, Simon G Thompson, Jonathan J Deeks, Douglas G Altman. BMJ 2003
14

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. BMJ 2009
12

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
Alessandro Liberati, Douglas G Altman, Jennifer Tetzlaff, Cynthia Mulrow, Peter C Gøtzsche, John P A Ioannidis, Mike Clarke, P J Devereaux, Jos Kleijnen, David Moher. BMJ 2009
9

Estimating the mean and variance from the median, range, and the size of a sample.
Stela Pudar Hozo, Benjamin Djulbegovic, Iztok Hozo. BMC Med Res Methodol 2005
9

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
David Moher, Larissa Shamseer, Mike Clarke, Davina Ghersi, Alessandro Liberati, Mark Petticrew, Paul Shekelle, Lesley A Stewart. Syst Rev 2015
6


GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.
Gordon Guyatt, Andrew D Oxman, Elie A Akl, Regina Kunz, Gunn Vist, Jan Brozek, Susan Norris, Yngve Falck-Ytter, Paul Glasziou, Hans DeBeer,[...]. J Clin Epidemiol 2011
6

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
Gordon H Guyatt, Andrew D Oxman, Gunn E Vist, Regina Kunz, Yngve Falck-Ytter, Pablo Alonso-Coello, Holger J Schünemann. BMJ 2008
6

Meta-analysis in clinical trials.
R DerSimonian, N Laird. Control Clin Trials 1986
5

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
Alessandro Liberati, Douglas G Altman, Jennifer Tetzlaff, Cynthia Mulrow, Peter C Gøtzsche, John P A Ioannidis, Mike Clarke, P J Devereaux, Jos Kleijnen, David Moher. J Clin Epidemiol 2009
5


Quantifying publication bias in meta-analysis.
Lifeng Lin, Haitao Chu. Biometrics 2018
178
5

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. Int J Surg 2010
5

Methodological index for non-randomized studies (minors): development and validation of a new instrument.
Karem Slim, Emile Nini, Damien Forestier, Fabrice Kwiatkowski, Yves Panis, Jacques Chipponi. ANZ J Surg 2003
4

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. Ann Intern Med 2009
4

Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.
D F Stroup, J A Berlin, S C Morton, I Olkin, G D Williamson, D Rennie, D Moher, B J Becker, T A Sipe, S B Thacker. JAMA 2000
4

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.
Larissa Shamseer, David Moher, Mike Clarke, Davina Ghersi, Alessandro Liberati, Mark Petticrew, Paul Shekelle, Lesley A Stewart. BMJ 2015
4

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
4

GRADE guidelines: 3. Rating the quality of evidence.
Howard Balshem, Mark Helfand, Holger J Schünemann, Andrew D Oxman, Regina Kunz, Jan Brozek, Gunn E Vist, Yngve Falck-Ytter, Joerg Meerpohl, Susan Norris,[...]. J Clin Epidemiol 2011
4


Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. J Clin Epidemiol 2009
3


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
3

Quantifying heterogeneity in a meta-analysis.
Julian P T Higgins, Simon G Thompson. Stat Med 2002
3

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
3

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
3

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
3


The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.
Brian Hutton, Georgia Salanti, Deborah M Caldwell, Anna Chaimani, Christopher H Schmid, Chris Cameron, John P A Ioannidis, Sharon Straus, Kristian Thorlund, Jeroen P Jansen,[...]. Ann Intern Med 2015
3

Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range.
Dehui Luo, Xiang Wan, Jiming Liu, Tiejun Tong. Stat Methods Med Res 2018
432
3

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.
Jonathan Ac Sterne, Miguel A Hernán, Barnaby C Reeves, Jelena Savović, Nancy D Berkman, Meera Viswanathan, David Henry, Douglas G Altman, Mohammed T Ansari, Isabelle Boutron,[...]. BMJ 2016
3

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
Matthew J Page, Joanne E McKenzie, Patrick M Bossuyt, Isabelle Boutron, Tammy C Hoffmann, Cynthia D Mulrow, Larissa Shamseer, Jennifer M Tetzlaff, Elie A Akl, Sue E Brennan,[...]. BMJ 2021
450
3

Evaluating non-randomised intervention studies.
J J Deeks, J Dinnes, R D'Amico, A J Sowden, C Sakarovitch, F Song, M Petticrew, D G Altman. Health Technol Assess 2003
2

The interpretation of random-effects meta-analysis in decision models.
A E Ades, G Lu, J P T Higgins. Med Decis Making 2005
481
2


Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis.
Jørn Wetterslev, Kristian Thorlund, Jesper Brok, Christian Gluud. J Clin Epidemiol 2008
954
2

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
Alessandro Liberati, Douglas G Altman, Jennifer Tetzlaff, Cynthia Mulrow, Peter C Gøtzsche, John P A Ioannidis, Mike Clarke, P J Devereaux, Jos Kleijnen, David Moher. PLoS Med 2009
2

Checking consistency in mixed treatment comparison meta-analysis.
S Dias, N J Welton, D M Caldwell, A E Ades. Stat Med 2010
957
2

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
216
2

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
948
2

Meta-analysis of individual participant data: rationale, conduct, and reporting.
Richard D Riley, Paul C Lambert, Ghada Abo-Zaid. BMJ 2010
797
2

RoB 2: a revised tool for assessing risk of bias in randomised trials.
Jonathan A C Sterne, Jelena Savović, Matthew J Page, Roy G Elbers, Natalie S Blencowe, Isabelle Boutron, Christopher J Cates, Hung-Yuan Cheng, Mark S Corbett, Sandra M Eldridge,[...]. BMJ 2019
2

How should meta-regression analyses be undertaken and interpreted?
Simon G Thompson, Julian P T Higgins. Stat Med 2002
2

A basic introduction to fixed-effect and random-effects models for meta-analysis.
Michael Borenstein, Larry V Hedges, Julian P T Higgins, Hannah R Rothstein. Res Synth Methods 2010
2


Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry.
Jaime L Peters, Alex J Sutton, David R Jones, Keith R Abrams, Lesley Rushton. J Clin Epidemiol 2008
666
2

Immediate effects of electroacupuncture and manual acupuncture on pain, mobility and muscle strength in patients with knee osteoarthritis: a randomised controlled trial.
Ralph Plaster, Wellington Bueno Vieira, Flávia Alves Duarte Alencar, Eduardo Yoshio Nakano, Richard Eloin Liebano. Acupunct Med 2014
26
7

PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews.
Abigail M Methley, Stephen Campbell, Carolyn Chew-Graham, Rosalind McNally, Sudeh Cheraghi-Sohi. BMC Health Serv Res 2014
326
2


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.